for nonsense mutation Duchenne muscular dystrophy
PTC Therapeutics withdrew its NDA resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy on 2026-02-12. Resubmission had followed prior FDA rejections; the company elected to withdraw rather than pursue further FDA review.
Duchenne muscular dystrophy is a genetic muscle-wasting disease that primarily affects boys, progressively weakening the muscles needed for movement and heart function. Translarna (ataluren) is designed to help the body's cellular machinery ignore certain genetic "stop" signals, allowing it to produce a functional dystrophin protein. By enabling the production of this crucial muscle protein, the drug aims to address the underlying cause of the disease and potentially slow its progression.
Duchenne/Becker muscular dystrophy (DBMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function
Source: ClinicalTrials.gov